VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer

Détails bibliographiques
Auteurs principaux:	Redchenko, I, Cappuccini, F, Pollock, E, Bryant, R, Carter, L, Verrill, C, Hollidge, J, Goodwin, L, Harrop, R, Romero, P, Vigano, S, Evans, T, Catto, J, Hamdy, F, Hill, A
Format:	Conference item
Publié:	American Society of Clinical Oncology 2018

Documents similaires